RBM6 Knockout A-549 Cell Line
Cat.No.:
EDC90408
Species:
Human
Cell Name:
A-549
Gene:
RBM6
Gene ID:
10180
Size:
1×10⁶ cells
RBM6 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC90408 |
|---|---|
| Product Name | RBM6 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | RBM6 |
| NCBI Gene ID | |
| Gene Synonyms | 3G2|DEF-3|DEF3|HLC-11|NY-LU-12|g16 |
| Summary |
Enables RNA binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4, 2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying RBM6 function, RBM6 Knockout A-549 Cell Line or RBM6 overexpression A-549 Cell Line?
The choice depends on whether you are studying RBM6's role as an RNA-binding protein and putative splicing factor or its emerging functions in cancer biology and tumor suppression. The Knockout line is appropriate for asking whether RBM6 is required for alternative splicing of specific transcripts — RBM6 has been characterized as a splicing factor with potential tumor suppressor activity in lung cancer. Overexpression is useful for studying RBM6's reported anti-proliferative effects in cancer contexts.
For RNA-binding protein research, the EDITGENE RBM6 Knockout in A-549 enables study of splicing regulation in a lung cancer context — RBM6 has been mapped to 3p21 (a frequently deleted region in lung cancer), and its loss may contribute to NSCLC progression. Rescue with wild-type or RNA-binding-deficient RBM6 enables structure-function studies. The knockout is valuable for characterizing RBM6-dependent splicing events through RNA-seq with rMATS or similar splicing-aware analysis.
What are the application scenarios for this model?
Primary applications:
• Alternative splicing analysis: RNA-seq with rMATS or MAJIQ to identify RBM6-dependent alternative splicing events in lung cancer cells.
• RNA-protein interaction studies: CLIP-seq or RIP-seq to map RBM6 RNA binding sites; the knockout serves as a critical specificity control.
• Lung cancer phenotype: proliferation, anchorage-independent growth, and apoptosis given RBM6's 3p21 chromosomal location and potential tumor suppressor function.
• Transcriptomic profiling: gene expression and isoform-level analysis to characterize the RBM6-dependent transcriptome.
EDITGENE recommends this model for researchers investigating RBM6-dependent splicing regulation and 3p21-associated lung cancer biology.
Is this RBM6 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. RBM6 rescue experiments require attention to its RNA-binding architecture:
• Construct design: use a codon-modified RBM6 sequence with a small C-terminal tag (FLAG, HA). RBM6 contains RNA recognition motifs (RRMs) and a G-patch domain — preserve all elements.
• RNA-binding-deficient rescue: RRM-canonical residue mutations (e.g., conserved aromatic residues in RNP1/RNP2 motifs) abolish RNA binding and serve as the standard specificity control.
• Splicing reporter assays: cell-based minigene splicing assays test rescue of RBM6-dependent splicing events.
• Functional readout: rescue should restore RBM6-dependent alternative splicing patterns identified during knockout characterization.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download